Managed Access Program to Provide Alpelisib for Patients With HR+ Advanced or Metastatic Breast Cancer

Summary

The purpose of this Cohort Treatment Plan is to allow access to alpelisib for eligible patients diagnosed with hormone receptor positive, advanced or metastatic breast cancer harboring a phosphatidylinositol 3-kinase (PI3K)CA mutation. The patient's Treating Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Hester A, Henze F, Travi C, Harbeck N, Wuerstlein R. First Experiences with Alpelisib in Clinical Routine: Case Reports from a German Breast Center. Breast Care (Basel). 2021 Apr;16(2):129-134. doi: 10.1159/000514794. Epub 2021 Mar 15.

Drugs

Indications